3 April 2023 ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder
15 March 2023 ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/refractory FLT3-mutant acute myeloid leukemia patients
13 March 2023 ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disorders
22 February 2023 ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
17 February 2023 ORYZON reports financial results and corporate update for quarter ended December 31, 2022